Background
Methods
Patients
Clinical and laboratory evaluation
Pentraxin3 measurements
Determination of the visceral and subcutaneous fat areas
Pathology
Statistical analysis
Results
Patients Characteristics
(NASH) (n = 42) | Non-NASH (n = 28) | |
---|---|---|
Steatosis grade | ||
1 | 22 | 20 |
2 | 17 | 6 |
3 | 3 | 2 |
Inflammatory activity | ||
0 | 4 | 11 |
1 | 27 | 17 |
2 | 9 | 0 |
3 | 2 | 0 |
Fibrosis stage | ||
0 | 0 | 28 |
1 | 21 | 0 |
2 | 4 | 0 |
3 | 11 | 0 |
4 | 6 | 0 |
Non-NASH patients | NASH patients | P value | |
---|---|---|---|
Age (years) | 49.0 ± 15.3 | 52.8 ± 13.5 | 0.2995 |
BMI (m/kg2) | 27.6 ± 5.1 | 28.9 ± 6.0 | 0.3989 |
VFA (cm2) | 128.6 ± 55.7 | 133.3 ± 58.8 | 0.8031 |
SFA (cm2) | 196.9 ± 61.4 | 232.5 ± 120.9 | 0.3765 |
AST (U/ml) | 35.7 ± 17.5 | 63.4 ± 40.7 | 0.0031 |
ALT (U/ml) | 56.8 ± 31.5 | 89.9 ± 55.7 | 0.0115 |
FBS (mg/dl) | 118.7 ± 39.9 | 118.2 ± 30.8 | 0.9586 |
IRI (ul/ml) | 13.6 ± 10.8 | 14.3 ± 8.2 | 0.7999 |
HOMA-IR | 3.47 ± 2.64 | 4.05 ± 2.54 | 0.4725 |
HDL cholesterol (mg/l) | 50.3 ± 12.6 | 49.3 ± 11.4 | 0.7463 |
LDL cholesterol (mg/l) | 133.7 ± 27.0 | 128.6 ± 39.3 | 0.5928 |
Triglyceride (mg/l) | 159.0 ± 48.9 | 162.8 ± 81.9 | 0.8502 |
Albumin | 4.51 ± 0.28 | 4.45 ± 0.51 | 0.6175 |
Platelet count | 25.8 ± 5.7 | 23.2 ± 8.0 | 0.1816 |
Hyaluronic acid (ng/dl) | 21.6 ± 15.1 | 50.1 ± 50.2 | 0.0373 |
Type IV collagen 7s (ng/dl) | 4.41 ± 0.98 | 5.14 ± 1.31 | 0.0611 |
Stages 0–2 NAFLD | Stages 3–4 NAFLD | P value | |
---|---|---|---|
Age (years) | 51.5 ± 13.4 | 52.8 ± 15.1 | 0.7564 |
BMI (m/kg2) | 28.1 ± 4.9 | 30.2 ± 6.7 | 0.2133 |
VFA (cm2) | 132.1 ± 63.7 | 135.7 ± 33.4 | 0.8716 |
SFA (cm2) | 216.9 ± 95.3 | 256.8 ± 108.2 | 0.0626 |
AST (U/ml) | 54.6 ± 41.0 | 58.1 ± 26.9 | 0.7526 |
ALT (U/ml) | 80.3 ± 49.3 | 82.4 ± 59.5 | 0.8903 |
FBS (mg/dl) | 122.9 ± 39.9 | 112.3 ± 17.8 | 0.3598 |
IRI (ul/ml) | 13.0 ± 9.06 | 18.3 ± 9.10 | 0.0762 |
HOMA-IR | 3.56 ± 2.59 | 5.16 ± 2.43 | 0.0677 |
HDL cholesterol (mg/l) | 50.1 ± 12.5 | 47.8 ± 10.2 | 0.5277 |
LDL cholesterol (mg/l) | 130.6 ± 33.3 | 129.8 ± 41.0 | 0.9430 |
Albumin (mg/l) | 4.55 ± 0.27 | 4.23 ± 0.66 | 0.0170 |
Platelet count (ng/ml) | 25.8 ± 6.6 | 20.0 ± 8.7 | 0.0134 |
Hyaluronic acid (ng/dl) | 32.7 ± 27.8 | 72.4 ± 68.1 | 0.0090 |
Type IV collagen 7s (ng/dl) | 4.65 ± 0.93 | 5.94 ± 1.53 | 0.0018 |
Hepatic fibrosis and plasma PTX3 levels
Relation between plasma PTX3 and grade of hepatic steatosis or grade of necroinflammation
Receiver operating characteristic (ROC) curves for differentiating between NASH and non-NASH based on the plasma PTX3 level
ROC curves for differentiating between stages 0–2 NAFLD and stages 3–4 NAFLD based on the plasma PTX3 level
Multiple regression analysis for demographic factors in the NASH patients
Factor | Odds ration | 95% CI | p Value |
---|---|---|---|
plasma PTX3 level (ng/ml) | 0.254 | 0.059 – 0.984 | 0.0488 |
AST (U/ml) | 0.984 | 0.910 – 1.064 | 0.692 |
ALT (U/ml) | 1.008 | 0.954 – 1.065 | 0.7699 |
Type IV collagen 7s domain (ng/ml) | 1.128 | 0.407 – 3.124 | 0.8171 |
hyaluronic acid (ng/ml) | 0.965 | 0.908 – 1.025 | 0.2499 |